---
document_datetime: 2023-09-21 21:29:37
document_pages: 14
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sycrest-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: sycrest-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 9.0106296
conversion_datetime: 2025-12-25 13:14:14.562474
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sycrest

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0046            | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 07/12/2022                          |                                             | Annex II and PL                  |           |
| IA/0044              | A.7 - Administrative change - Deletion of manufacturing sites                                                              | 15/12/2021                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| N/0043            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                     | 27/10/2021   |            | PL              |                                   |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------|
| PSUSA/256/2 02008 | Periodic Safety Update EU Single assessment - asenapine                                                                                                                                                                                                                                                                                                                                                                                              | 11/03/2021   | n/a        |                 | PRAC Recommendation - maintenance |
| N/0042            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                     | 25/02/2021   |            | PL              |                                   |
| IB/0040/G         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation | 12/02/2021   | n/a        |                 |                                   |
| N/0041            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                     | 18/01/2021   |            | PL              |                                   |
| N/0039            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                     | 11/12/2020   | 04/02/2021 | PL              |                                   |
| IA/0037           | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                        | 28/07/2020   | 04/02/2021 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0036           | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                               | 29/06/2020   | n/a        |                                  |                                   |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------|
| PSUSA/256/2 01908 | Periodic Safety Update EU Single assessment - asenapine                                                                                                                                                                                                                                                                                                                                           | 12/03/2020   | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0035           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                    | 21/01/2020   | 04/02/2021 | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/256/2 01808 | Periodic Safety Update EU Single assessment - asenapine                                                                                                                                                                                                                                                                                                                                           | 14/03/2019   | n/a        |                                  | PRAC Recommendation - maintenance |
| IA/0033           | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                        | 04/01/2019   | n/a        |                                  |                                   |
| II/0031/G         | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered | 17/05/2018   | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

|                   | of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                                  |                                                                                                                                                                                                                                                                               |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/256/2 01708 | Periodic Safety Update EU Single assessment - asenapine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 08/03/2018 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                             |
| II/0030           | Update of sections 4.4 and 4.8 of the SmPC to add safety information regarding falls as a result of postmarketing reports and published literature review. The package leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives for Denmark, Norway, Slovenia and Slovakia in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.0. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 08/02/2018 | 07/02/2019 | SmPC, Annex II, Labelling and PL | Asenapine may cause adverse effects such as somnolence, orthostatic hypotension, dizziness and extrapyramidal symptoms, which may lead to falls and, consequently, fractures or other injuries. Patients at risk for fall should be evaluated prior to prescribing asenapine. |
| IB/0028           | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                       | 17/07/2017 | n/a        |                                  |                                                                                                                                                                                                                                                                               |
| IA/0027           | B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 09/03/2017 | n/a        |                                  |                                                                                                                                                                                                                                                                               |
| PSUSA/256/2 01608 | Periodic Safety Update EU Single assessment - asenapine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 09/03/2017 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| IAIN/0025/G       | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                          | 13/07/2016   | 31/05/2017   | Annex II and PL   |                                   |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-----------------------------------|
| IA/0024           | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                          | 03/06/2016   | n/a          |                   |                                   |
| PSUSA/256/2 01508 | Periodic Safety Update EU Single assessment - asenapine                                                                                                                                                                                                                                                                                                                                                                                                                                               | 17/03/2016   | n/a          |                   | PRAC Recommendation - maintenance |
| II/0020           | Update of section 4.2 of the SmPC in order to change the starting therapeutic dose to 5mg BID based on the results of an exploratory dose finding study (P05691) conducted to establish the optimal dosing regimen for manic episodes in bipolar disorder. Section 5.1 of the SmpC is updated to reflect the results of the study and minor consequential changes are introduced in sections 4.8 and 5.1 of the SmPC. Section 5.2 of the SmPC is updated in line with CHMP conclusions from variation | 24/09/2015   | 28/10/2015   | SmPC and PL       |                                   |

<div style=\"page-break-after: always\"></div>

|         | the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                 |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0021 | Update of sections 4.2, 4.8 and 5.1 of the SmPC with information on long-term safety and efficacy generated in paediatric study P05898, a 50-week open-label, flexible-dose, extension to study P06107 in paediatric subjects with acute manic or mixed episodes associated with bipolar 1 disorder, submitted according to Article 46 of the paediatric regulation. Study P05898 is part of the PIP P/0299/2014. The Package Leaflet has been updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 24/09/2015 | 28/10/2015 | SmPC        | Long term safety in the paediatric population (ages 10 17 years) with manic or mixed episodes associated with bipolar I disorder population was explored in a 50 week, open label, uncontrolled extension study. In this trial, a total of 34.8 %of subjects experienced clinically significant weight increase (i.e., ≥ 7 %increase in body weight at endpoint). Overall mean (SD) weight gain at study endpoint was 3.5 (5.76) kg. The clinically relevant adverse reactions identified in the paediatric trials were generally similar to those observed in the adult trials. However, adverse effects of treatment on weight gain and on plasma lipid profile appeared to be greater than effects observed in the adult trials. Long term efficacy could not be established in the trial. |
| II/0022 | Update of SmPC section 4.8, upon request by the CHMP following the assessment of the renewal application R-19, to revise the frequency classification of some of the already listed adverse drug reactions and to highlight the fact that serious hypersensitivity reactions have been reported. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the                                                                                                                                                                            | 06/08/2015 | 28/10/2015 | SmPC and PL | Frequency classifications were assigned to the following ADRs as follows: ' Allergic reactions ' Uncommon ≥ 0.1%<1%; ' Restless legs syndrome ' Uncommon ≥ 0.1%<1%; ' Nausea ' Common ≥ 1%<10%; ' Oral mucosal lesions ' Uncommon ≥ 0.1%<1%; ' Salivary hypersecretion ' Common ≥ 1%<10%; ' Drug withdrawal syndrome neonatal ' Unknown.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                   | Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0019            | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 26/02/2015 | 05/05/2015 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, the CHMP considered that the benefit-risk balance of Sycrest in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/256/2 01408 | Periodic Safety Update EU Single assessment - asenapine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12/02/2015 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0017           | Update of sections 4.2, 4.8, 5.1 and 5.2 of the Summary of Product Characteristics (SmPC) with pharmacokinetic, safety and efficacy information from studies in the paediatric population. The Package Leaflet has been updated accordingly. Additionally, the MAH took the opportunity to introduce minor editorial changes throughout the annexes. Furthermore, the contact details of the local representatives in the Package Leaflet have been updated. The MAH took this opportunity to amend the Route of Admistration in Annex A from 'Oral use' to 'Sublingual use'. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 20/11/2014 | 05/05/2015 | SmPC, Annex II and PL            | Based on the provided data, information related to pharmacokinetics, safety and efficacy in paediatric population was included in the product information of Sycrest. In a PK study using flavoured sublingual tablets, at the 5 mg and 10 mg twice daily dose level, asenapine pharmacokinetics in a paediatric population (10 to 17 years of age, inclusive) are similar to those observed in adults. The 10 mg twice daily dose resulted in an approximate dose proportional increase in asenapine exposure compared to 5 mg twice daily. Based on this small pharmacokinetic study, paediatric patients appeared to be more sensitive to dystonia with initial dosing with asenapine when a gradual up-titration schedule was not followed. The incidence of dystonia in paediatric clinical trials using a gradual up- |

<div style=\"page-break-after: always\"></div>

| data   | titration was similar to that seen in adult trials.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|        | The safety and efficacy of Sycrest was evaluated in 403 paediatric patients with bipolar I disorder who participated in a single, 3 week, placebo controlled, double blind trial, of whom 302 patients received Sycrest at fixed doses ranging from 2.5 mg to 10 mg twice daily. Study results showed statistically significant superiority for all three Sycrest doses in improving the Young Mania Rating Scale (YMRS) total score as measured by the change from baseline to Day 21, as compared with placebo. However, the clinical relevance of the efficacy findings has not been established. No long term data are available with regard to the efficacy and the safety of asenapine in this population. The mean change from baseline to endpoint in weight for placebo and asenapine 2.5 mg, 5 mg, and 10 mg twice daily, was 0.48, 1.72, 1.62, and 1.44 kg, respectively. The proportion of subjects with clinically significant weight gain ( ≥ 7 %weight gain from baseline at endpoint) was 14.1% for asenapine 2.5 mg twice daily, 8.9 %for asenapine 5 mg twice daily, and 9.2 %for asenapine 10 mg twice daily, compared to 1.1 %for placebo. Efficacy of Sycrest was not demonstrated in an 8 week, placebo controlled, double blind, randomized, fixed dose trial in 306 adolescent patients aged 12 17 years with schizophrenia at doses of 2.5 and 5 mg twice daily. The clinically relevant adverse experiences identified in the paediatric bipolar and schizophrenia trials were similar to |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                     |            |            | The most common adverse reactions ( ≥ 5 %and at least twice the rate of placebo) reported in paediatric patients with bipolar I disorder were somnolence, sedation, dizziness, dysgeusia, hypoaesthesia oral, paraesthesia oral, nausea, increased appetite, fatigue, and weight increased. The most common adverse reactions (proportion of patients 5 %and at least twice placebo) reported in paediatric patients with schizophrenia were somnolence, sedation, akathisia, dizziness, and hypoaesthesia oral. There was a statistically significant higher incidence of patients with ≥ 7 %weight gain (from baseline to endpoint) compared to placebo (3.1 %) for Sycrest 2.5 mg twice daily (9.5 %) and Sycrest 5 mg twice daily (13.1 %).   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0014 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                              | 06/03/2014 | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IG/0404   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                        | 14/02/2014 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| N/0015    | The MAH took this opportunity to include the Croatian PI and to introduce the Croatian affiliate in the list of local representatives. Also local representatives for Finland and Greece were corrected together with minor changes in the local representatives address list in the Swedish text. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 23/01/2014 | 11/02/2014 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| IG/0366   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                              | 08/11/2013   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0012   | Update of section 4.8 of the SmPC in order to update the safety information to include ' angioedema ' as an adverse reaction, based on post-marketing reports. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                        | 21/02/2013   | 11/02/2014 | SmPC, Annex II and PL | Based on post-marketing reports, a safety signal of angioedema was identified by the Marketing Authorisation Holder. Therefore, they proposed to update section 4.8 of the SmPC to include angioedema and the corresponding change to section 4 of the Package Leaflet. The CHMP considered the changes to be acceptable and agreed on the amendments to be introduced. |
| II/0011   | Update of section 4.8 of the SmPC in order to add a new adverse reaction \"salivary hypersecretion\" based on post marketing reports. The Package Leaflet was updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the Annex II is brought in line with the latest QRD template version 8.2. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 13/12/2012   | 11/02/2014 | SmPC, Annex II and PL | The CHMP reviewed the post-marketing safety data on salivary hypersecretion and concluded on the need to include the following side-effect in the Product Information: increased saliva (drooling).                                                                                                                                                                     |
| IB/0010   | Update of section 4.8 of the SmPC in order to add a new adverse reaction \"salivary hypersecretion\" based on post marketing reports. The Package Leaflet was                                                                                                                                                                                                                                                                                                                                                                                  | 17/10/2012   | 29/10/2012 | SmPC and PL           | The CHMP reviewed the post-marketing safety data on salivary hypersecretion and concluded on the need to include the following side-effect in the Product Information:                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|         | updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the Annex II is brought in line with the latest QRD template version 8.2. The requested variation introduced amendments to the SmPC, Annex II and Package Leaflet. C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH   |            |            |                                  | increased saliva (drooling).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0184 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 21/08/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0008 | Safety update to section 4.8 of the SmPC and section 4 of the PL to include additional adverse reactions. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                | 24/05/2012 | 27/06/2012 | SmPC, Annex II, Labelling and PL | Further to CHMP assessement of second PSUR as well as of cumulative review of post-marketing spontaneous reports, this variation is a safety update to section 4.8 of the SmPC and section 4 of the PL to include the following additional side-effects: - anaphylactic/anaphylactoid reactions - ulcers, soreness, redness, swelling and blisters within the mouth - unpleasant sensations in the legs (also called restless legs syndrome) - nausea oral mucosal lesions (ulcerations, blistering and inflammation), nausea and restless Legs syndrome) |

<div style=\"page-break-after: always\"></div>

| IG/0117/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 18/11/2011   | 18/11/2011   | Annex II    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0005     | Following PhVWP/CHMP conclusions of June 2011, update of the Summary of Product Characteristics (SmPC) and Package Leaflet (PL) regarding the use of antipsychotics during the third trimester of pregnancy and risk of abnormal muscle movements and/or withdrawal symptoms in newborns in accordance with the PhVWP/CHMP class labelling recommended wording. In addition, following a modification of the agreed Paediatric Investigation Plan, section 5.1 of the SmPC has been updated to remove the agreed measures related to schizophrenia. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a | 22/09/2011   | 24/10/2011   | SmPC and PL | There is evidence to suggest that the newborn babies of mothers treated with antipsychotics during the third trimester of pregnancy may suffer adverse effects (primarily extrapyramidal side effects and/or withdrawal effects). Whilst there is limited data available for some antipsychotics, this is likely to be a class effect. In addition to the inclusion of neonatal drug withdrawal syndrome as listed adverse reaction, section 4.6 of the SmPC and section 2 of the PL were updated in accordance with the PhVWP/CHMP class labelling recommended wording, as follows: SmpC: Neonates exposed to antipsychotics (including [Sycrest]) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and |

<div style=\"page-break-after: always\"></div>

|           | PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                                                                      |            |            |             | duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. PL: The following symptoms may occur in newborn babies, of mothers that have used [Sycrest] in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0003   | Update of SPC section 4.8 to include information on hypersensitivity reactions and PL section 4 to provide further information to the physicians and patients. Additionally minor spelling and typo corrections were made to the product information. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                              | 23/06/2011 | 27/07/2011 | SmPC and PL | Following the review of the post-marketing safety data the Product Information for Sycrest has been updated to reflect the fact that the treatment with asenapine can lead to allergic reactions, such as difficulty in breathing, swollen tongue or throat, skin rash, itching and increased heart rate. Patients must seek medical attention immediately if they experience these symptoms.                                                                                                                          |
| IA/0004/G | This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits | 20/04/2011 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| N/0001   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   | 27/01/2011   | n/a   | Annex II and PL   |
|----------|----------------------------------------------------------------------------------------------------|--------------|-------|-------------------|